What to Look For in the Pipeline, Misconceptions of Drug Approvals and More of ‘What’s on the Mind’ of Jeffrey Casberg

Podcast

Briana Contreras, an editor with Managed Healthcare Executive, and Peter Wehrwein, managing editor of MHE, got to chatting with the newest editorial advisory board member, Jeffrey Casberg, who is vice president of Clinical Pharmacy at IPD Analytics.

Briana Contreras, an editor with Managed Healthcare Executive, and Peter Wehrwein, managing editor of MHE, got to chatting with the newest editorial advisory board member, Jeffrey Casberg, who is vice president of Clinical Pharmacy at IPD Analytics.

Casberg is the newest member on the MHE editorial advisory board.

Casberg is the newest member on the MHE editorial advisory board.

In the discussion, Casberg shared the most pressing or prominent issues on his mind, he explained what the drug life-cycle is at IPD, and what the latest is on drugs in the pipeline. Casberg also shared his predictions for Sarepta Therapeutics’ DMD drug for young children and Mounjaro’s Type 2 Diabetes Drug, and even touched on some common misconceptions he notices about drug approvals, pricing and cost.

Recent Videos
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
Jennifer Seminerio, MD, a gastroenterologist
Jennifer Seminerio, MD, a gastroenterologist
Related Content
© 2024 MJH Life Sciences

All rights reserved.